Nivolumab vs Everolimus in Patients With Advanced RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nivolumab Versus Everolimus in Patients With Advanced Renal Cell Carcinoma: Updated Results With Long-Term Follow-Up of the Randomized, Open-Label, Phase 3 CheckMate 025 Trial
Cancer 2020 Jul 16;[EPub Ahead of Print], RJ Motzer, B Escudier, S George, HJ Hammers, S Srinivas, SS Tykodi, JA Sosman, ER Plimack, G Procopio, DF McDermott, D Castellano, TK Choueiri, F Donskov, H Gurney, S Oudard, M Richardet, K Peltola, AS Alva, M Carducci, J Wagstaff, C Chevreau, S Fukasawa, Y Tomita, TC Gauler, CK Kollmannsberger, FA Schutz, J Larkin, D Cella, MB McHenry, SS Saggi, NM TannirFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.